Plasminogen Activators

• 

  Subject Areas on Research

  • A colorimetric assay for releasable plasminogen activator. 
  • A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. 
  • A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. 
  • A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. 
  • ATP-regulated activity of the plasmin-streptokinase complex: a novel mechanism involving phosphorylation of streptokinase. 
  • Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. 
  • Alpha 2-macroglobulin is a binding protein for basic fibroblast growth factor. 
  • Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation. 
  • Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7. 
  • Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. 
  • Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Catabolic pathways for streptokinase, plasmin, and streptokinase activator complex in mice. In vivo reaction of plasminogen activator with alpha 2-macroglobulin. 
  • Catabolism of human tissue plasminogen activator in mice. 
  • Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. 
  • Characterization of keratinocyte plasminogen activator inhibitors and demonstration of the prevention of pemphigus IgG-induced acantholysis by a purified plasminogen activator inhibitor. 
  • Clinical Crossroads: a 36-year-old woman recuperating from stroke. 
  • Combinatorial mutagenesis of the reactive site region in plasminogen activator inhibitor I. 
  • Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. 
  • Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. 
  • Correlation of epidermal plasminogen activator activity with disease activity in psoriasis. 
  • Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. 
  • Diagnosis and treatment of acute coronary ischemic syndromes: a update for 1995. 
  • Differential expression of plasminogen activators and their inhibitors in an organotypic skin coculture system. 
  • Early operative intervention after thrombolytic therapy for primary subclavian vein thrombosis: an effective treatment approach. 
  • Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. 
  • Effects of exercise on the Type A (coronary prone) behavior pattern. 
  • Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. 
  • Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review. 
  • Epidermal plasminogen activator is abnormal in cutaneous lesions. 
  • Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. 
  • Expression of plasminogen activators in basal cell carcinoma. 
  • Extracellular annexin II. 
  • Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. 
  • Extravascular plasminogen activator and inhibitor activities detected at the site of a chronic mycobacterial-induced inflammation. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. 
  • Fibrinolytic therapy for acute ST-segment elevation myocardial infarction. 
  • Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Growth factor control of extracellular proteolysis. 
  • Hematologic and surgical management of the dental patient with plasminogen activator deficiency. 
  • Heparanase and platelet factor-4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM. 
  • Human epidermal plasminogen activator. Characterization, localization, and modulation. 
  • Human skin proteinases as inflammatory mediators. 
  • Identification of murine extra-embryonic endodermal cells by reaction with teratocarcinoma basement membrane antiserum. 
  • In vitro studies of acantholysis of keratinocytes induced by pemphigus antibody. 
  • Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis. 
  • Increased releasable vascular plasminogen activator and a bleeding diathesis. 
  • Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG. 
  • Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. 
  • Keratinocyte urokinase-type plasminogen activator is secreted as a single chain precursor. 
  • Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation. 
  • Life-long bleeding diathesis: effect of orthotopic liver transplantation. 
  • Lipoprotein (a): purification and kinetic analysis. 
  • Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen. 
  • Maximizing the benefits of thrombolytic therapy for acute myocardial infarction. 
  • Mechanical versus chemical thrombolysis: an in vitro differentiation of thrombolytic mechanisms. 
  • Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1(CD11b/CD18) and urokinase receptor (CD87). 
  • Mesenteric vein thrombosis and vascular plasminogen activator. 
  • Microassay for the photometric quantitation of cell-associated plasminogen activator using a chromogenic tripeptide substrate. 
  • Migrating keratinocytes express urokinase-type plasminogen activator. 
  • Molecular mechanisms of pathogenesis. 
  • Molecular size of secreted and cell-associated plasminogen activators from cultured epidermal cells. 
  • New advances in the management of acute coronary syndromes: 2. Fibrinolytic therapy for acute ST-segment elevation myocardial infarction. 
  • New aspects of pathogenesis of psoriasis. 
  • New dose regimens for coronary thrombolysis. 
  • North Carolina stroke prevention and treatment facilities survey: rtPA therapy for acute stroke. 
  • Off-hour admission and in-hospital stroke case fatality in the get with the guidelines-stroke program. 
  • Optical detection of polycations via polymer film-modified microtiter plates: response mechanism and bioanalytical applications. 
  • Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. 
  • Pathogenesis of autoimmunity in pemphigus. 
  • Penicillamine-induced pemphigus. Immunoglobulin from this patient induces plasminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus. 
  • Physical conditioning augments the fibrinolytic response to venous occlusion in healthy adults. 
  • Plasminogen activation stimulates an increase in intracellular calcium in human synovial fibroblasts. 
  • Plasminogen activators in epithelial biology. 
  • Platelet function and fibrinolytic agents: two sides of a coin? 
  • Polyoma virus infection of retinoic acid-induced differentiated teratocarcinoma cells. 
  • Pregnancy-induced changes in the fibrinolytic balance: evidence for defective release of tissue plasminogen activator and increased levels of the fast-acting tissue plasminogen activator inhibitor. 
  • Primary upper-extremity deep venous thrombosis. 
  • Production and secretion of proteolytic enzymes by normal and neoplastic cells. 
  • Production of extracellular proteolytic enzymes by neoplastic and normal epithelial cells. 
  • Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the "gold standard" for myocardial reperfusion assessment. 
  • Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Prognostic value of clinical markers of reperfusion in patients with acute myocardial infarction treated by thrombolytic therapy. 
  • Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy. 
  • Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. 
  • Receptors for maleylated proteins regulate secretion of neutral proteases by murine macrophages. 
  • Recurrent thrombosis of the superior vena cava associated with activated protein C resistance: imaging findings. 
  • Reteplase but not alteplase affects early soluble PECAM-1 and P-selectin release in patients with acute myocardial infarction. 
  • Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. 
  • Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion. 
  • Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. 
  • Simple and sensitive assay employing stable reagents for quantification of plasminogen activator. 
  • Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome. 
  • Skin abnormalities in mice transgenic for plasminogen activator inhibitor 1: implications for the regulation of desquamation and follicular neogenesis by plasminogen activator enzymes. 
  • Soluble vascular cell adhesion molecule-1 and E-selectin in patients with acute myocardial infarction treated with thrombolytic agents. 
  • Streptokinase versus alteplase in acute myocardial infarction. 
  • Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. 
  • TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. 
  • Teratocarcinoma differentiation: plasminogen activator activity associated with embryoid body formation. 
  • The effect of corticosteroids, dapsone and gold upon plasminogen activator synthesis and secretion by human epidermal cells cultured with pemphigus antibody. 
  • The immune consequences of trauma. 
  • The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? 
  • Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. 
  • Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. 
  • Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries. 
  • Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil. 
  • Transplantation of psoriatic skin onto nude mice. 
  • Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. 
  • Treating myocardial infarction in the post-GUSTO era. A US perspective. 
  • Uninvolved skin from psoriatic patients develops signs of involved psoriatic skin after being grafted onto nude mice. 
  • Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. 
  • Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies. 
  • Venous and arterial thromboembolic disease in women using oral contraceptives. 
  • Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor. 
  • Why is lipoprotein(a) relevant to thrombosis? 
  • mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. 
• 

  Keywords of People

  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Toth, Cynthia Ann, Joseph A.C. Wadsworth Distinguished Professor of Ophthalmology, Biomedical Engineering